Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium bromide in moderate to severe COPD (ACCORD COPD I)
NCT00363896Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2006
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Aclidinium 200 µg once-daily with Placebo (2 arms). Primary endpoint: Trough Forced Expiratory Volume in the First Second at 28 weeks. Started Jul 2006; status: completed.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00363896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363896.